, Singapore

Daily Markets Briefing: STI to open soft

Index closed largely unchanged at 3291.

IG Markets Singapore said:

Singapore’s STI remain resilient closed largely unchanged at 3291, we expect the STI to open soft this morning.

Meanwhile, OCBC Investment Research noted:

The sharp retreat by the European and US markets overnight is likely to spook the local bourse to a poor opening this morning.

And with the 2-week downtrend resistance still intact and the MACD still drifting lower at the moment, this suggests that the overall momentum is still more downside biased.

For now, we still see the immediate support at 3,265 (minor trough), followed by the subsequent base at the 3,240 key resistance-turned-support.

On the upside, the immediate resistance is now pegged at the 3,300 psychological hurdle and downtrend resistance, with the next obstacle marked at the 3,315 recent peak.

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare